Michelson Diagnostics Limited
Healthcare
Early Stage
2007
www.michelsondiagnostics.com
Michaelson Diagnostics Limited develops imaging products using a technology called Multi-Beam Optical Coherence Tomography (OCT). This technology enables in-vivo capture, visualisation and measurement of histopathology details that are too small to be seen with ultrasound, and too deep for conventional microscopy. It provides a unique way for a dermatologist to see detailsof a skin lesion quickly and non-invasively, so that earlier, more accurate, lower cost and less invasive treatments with a better clinical outcome can be applied and the progress of the treatment easily monitored. The Company's current VivoSight OCT scanner with hand-held probe is CE approved in Europe and has 510(k) FDA clearance in the USA for clinical use in dermatology clinics.
Though a platform technology, the Company's initial focus is on the diagnosis and treatment of Non-melanoma Skin Cancer which represents a very large market in which the advantages to both patients and dermatologists can be clealy demonstrated.
Our investment has supported the development, regulatory approvals and initial commercial traction of the company's devices.